Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience

  • Choi, Seo Hee (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Cho, Jaeho (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Kim, Jin Seok (Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Cheong, June-Won (Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Suh, Chang-Ok (Department of Radiation Oncology, Yonsei University College of Medicine)
  • Received : 2015.06.10
  • Accepted : 2015.08.03
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Follicular lymphoma (FL) is an indolent non-Hodgkin's lymphoma that is highly sensitive to radiotherapy (RT). However, the effectiveness of RT has not been well established. We reviewed our experiences to assess the role of RT for FL and analyze treatment results. Materials and Methods: Retrospective analysis was done on 29 patients who received first RT between January 2003 and August 2013. Of 23 early stage (stage I, II) patients, 16 received RT alone, four received chemotherapy followed by RT, two received RT postoperatively, and one received salvage RT for relapse after resection. Six advanced-stage (stage III, IV) patients received RT after chemotherapy: two received consolidation RT, three received salvage RT for residual lesions, and one received RT for progressive sites. Median RT dose was 30.6 Gy (range, 21.6 to 48.6 Gy). Median follow-up duration was 62 months (range, 6 to 141 months). Results: All patients showed complete response in the radiation field. Eight outfield relapses were reported. Seven patients received salvage treatment (three chemotherapy, four RT). Four patients showed excellent responses, especially to RT. Estimated 5-year and 10-year relapse-free survivals were 72% and 60%. In the RT-alone group, 5-year relapse-free survival was 74.5%. All advanced-stage patients were disease-free with 100% 5-year overall survival. Disease-specific death was noted in only one patient; four others died of other unrelated causes. No significant toxicity was reported. Conclusion: RT resulted in excellent treatment outcomes for all FL stages when used as a primary treatment modality for early stage or salvage-treatment modality for advanced-stage disease.

Keywords

References

  1. Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third Nationwide Study. Korean J Pathol 2011;45:254-60. https://doi.org/10.4132/KoreanJPathol.2011.45.3.254
  2. Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of firstline management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30:3368-75. https://doi.org/10.1200/JCO.2011.40.6546
  3. Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 2014;12: 916-46. https://doi.org/10.6004/jnccn.2014.0086
  4. Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24:561-76. https://doi.org/10.1093/annonc/mds517
  5. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:928-34. https://doi.org/10.1016/j.ijrobp.2005.08.010
  6. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumorburden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-7. https://doi.org/10.1200/JCO.1997.15.3.1110
  7. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-22. https://doi.org/10.1016/S0140-6736(03)14110-4
  8. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32. https://doi.org/10.1182/blood-2005-01-0016
  9. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. https://doi.org/10.1182/blood-2004-08-3175
  10. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92. https://doi.org/10.1200/JCO.2006.06.4618
  11. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31. https://doi.org/10.1182/blood-2008-04-153189
  12. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86. https://doi.org/10.1200/JCO.2007.13.5376
  13. Russo AL, Chen YH, Martin NE, et al. Low-dose involvedfield radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 2013;86:121-7. https://doi.org/10.1016/j.ijrobp.2012.12.024
  14. Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol 2014; 15:457-63. https://doi.org/10.1016/S1470-2045(14)70036-1
  15. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27: 4555-62. https://doi.org/10.1200/JCO.2008.21.3991
  16. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991;2 Suppl 2:123-9. https://doi.org/10.1093/annonc/2.suppl_2.123
  17. Leonard RC, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma: the Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991;2:655-62. https://doi.org/10.1093/oxfordjournals.annonc.a058044
  18. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage IIIIV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients: a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-505. https://doi.org/10.1200/JCO.1999.17.8.2499
  19. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-9.
  20. Solal-Celigny, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. https://doi.org/10.1182/blood-2003-12-4434
  21. Federico M, Guglielmi C, Luminari S, et al. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens: a GISL study. Haematologica 2007;92:1482-8. https://doi.org/10.3324/haematol.11502
  22. Frank C, Zierhut D, Schulz-Ertner D, Wannenmacher M. Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001;177:597-603. https://doi.org/10.1007/PL00002370
  23. Ha CS, Kong JS, Tucker SL, et al. Central lymphatic irradiation for stage I-III follicular lymphoma: report from a singleinstitutional prospective study. Int J Radiat Oncol Biol Phys 2003;57:316-20. https://doi.org/10.1016/S0360-3016(03)00592-3
  24. Ahmed N, Owen TE, Rubinger M, et al. Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. PLoS One 2013;8:e65156. https://doi.org/10.1371/journal.pone.0065156
  25. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7. https://doi.org/10.1200/JCO.2002.08.674
  26. Bachy E, Houot R, Morschhauser F, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVPinterferon plus rituximab in follicular lymphoma. Haematologica 2013;98:1107-14. https://doi.org/10.3324/haematol.2012.082412
  27. Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:1506-13. https://doi.org/10.1200/JCO.2012.45.0866
  28. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10. https://doi.org/10.1016/S0140-6736(12)61763-2
  29. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944-52. https://doi.org/10.1182/blood-2013-11-531327
  30. De Los Santos JF, Mendenhall NP, Lynch JW Jr. Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 1997;38:3-8. https://doi.org/10.1016/S0360-3016(96)00631-1
  31. McClanahan F, Hielscher T, Rieger M, et al. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy. Eur J Haematol 2010;85:11-9.

Cited by

  1. Treatment outcome of diffuse large B-cell lymphoma involving the head and neck : Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy vol.96, pp.25, 2015, https://doi.org/10.1097/md.0000000000007268
  2. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-01851-w